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Abstract 
Molecular biomarkers have become one of the cornerstones of oncological pathology. 
The method of classification not only directly affects the manner in which patients are 
diagnosed and treated, but also guide the development of drugs and of artificial 
intelligence tools.  This work aims to organize and update gastrointestinal molecular 
biomarkers in order to produce an easy-to-use guide for routine diagnostics. For this 
purpose, we have extracted and re-organized the molecular information of epithelial 
neoplasms included in the new “WHO Classification of Tumours of the Digestive System” 








In the era of molecular medicine, with the expansion of digital pathology and the 
revolution of artificial intelligence (AI), molecular biomarker classifications of cancer are 
more important than ever before.1 A rational cancer taxonomy is necessary to 
standardize diagnoses, make  decisions on biomarker/drug development and generate 
an appropriate  background  for AI tools.2 Molecular biomarkers have a prominent  role in 
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unified classification for biomarkers is important to collect relevant information and keep it 
updated. This represents a challenge for modern (morpho-molecular) pathologists.3
The value of biomarkers in routine tissue diagnostics
A “biomarker” is defined as “any substance, structure, or process that can be measured 
in the body or its products and influence or predict the incidence of outcome or disease”.4 
Every year, there are  between 15,000 to 20,000 new scientific articles on cancer 
biomarkers.5 Unfortunately, from every 100 such biomarkers, less than 1% make it into a 
form that is useful for patient diagnosis or stratification 6, mostly due to a variety  of 
scientific and technical reasons.7 
As a result, there is no clear-cut evidence in the literature as to which biomarkers 
are essential for diagnostics and/or therapeutic decision-making. However, the World 
Health Organization (WHO) Classification of Tumours consensus of international experts 
represents the best indication of how relevant these biomarkers are in routine diagnostic 
practice. Our goal is to summarize the use of these biomarkers in the gastrointestinal 
system (from oesophagus to anal canal), and obtain indications of the specific weight, 
form and relevance of biomarker analysis in disease taxonomy and clinical decision-
making. 
Current biomarker classification and proposed subcategorization.
A biomarker is a characteristic that is objectively measured and evaluated as an indicator 
of normal/pathogenic processes or pharmacologic therapeutic responses.8 The 5th 
Edition WHO Tumour Classification of Digestive System Tumours includes diagnostic, 
predictive, and prognostic molecular biomarkers as the major  categories.9 Diagnostic 
biomarkers are intended to help pathologists establish a specific diagnosis; predictive 
markers indicate the probability of benefiting from a specific therapy; and prognostic ones 
determine the outcome of patients, in the absence of specific treatments.8 
The decision as to which group a biomarker belongs to represents the first step of 
assessment. Some biomarkers may fullfill the criteria for more than one category as well. 
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organization and comprehension. In this manner, for diagnostic biomarkers, the second 
step is to determine if it is useful in differential diagnosis or if it contributes to cancer 
classification. For predictive biomarkers, the following question should be asked: Are 
there definitive randomised clinical trials or cohort studies that support their efficacy? If 
the answer is yes, then these would correspond to established predictive biomarkers. If 
the answer is negative, but they are currently under investigation, one may classify them 
as a “potentially predictive biomarkers”. If they are not yet associated with any clinical 
trial, we propose to label them by the term “pre/clinical predictive biomarkers”. In this 
circumstance, it is unlikely that they would be designated within one of the first level 
groups within the WHO Classification of Tumours, although they often have relevance to 
the understanding of tumour pathogenesis and may be included under this topic. For 
prognostic biomarkers, the main question is whether they are prognostic specific markers 
for a certain entity, or whether they are used to create risk stratification groups.  
Biomarkers that do not fit into any of these categories should be classified as "Others". 
This classification is summarized in figure 1.
However, in order to understand, adequately categorize, and subcategorize these 
biomarkers, it is necessary to methodically evaluate other attributes associated with 
them.
Variables to consider in the categorization of biomarkers:
1. Context: System, organ and entity.
Context is a relevant aspect to consider in any biomarker assessment. A specific 
biomarker can have different attributes depending on the location (system/organ) and 
the disease (entity) in question. For example, the presence of EGFR (epidermal 
growth factor receptor) activating mutations in oesophageal squamous cell carcinoma 
is an adverse prognostic factor, and EGFR targeted therapies have failed to improve 
survival.10-12 The same molecular alterations in non-small cell lung carcinoma 
(NSCLC) confer a better prognosis and also provide the patient with an opportunity to 
receive tyrosine kinase inhibitors (TKIs) therapy with a significant chance of improved 
survival.13 Activating mutations of BRAF (v-raf murine sarcoma viral oncogene 
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therapy and helps establish a worse prognosis14; while the same alterations (BRAF 
V600E activating mutation) in melanoma predict response to treatment with BRAF 
inhibitors, such as Vemurafenib.15 Sometimes, the existence of certain molecular 
alterations are known, but there are no clinical trials available that support their 
routine use. On other occasions, support exists for a specific organ, but not for others. 
An example of this is ERBB2 (HER2-human epidermal growth factor receptor 2) 
mutation in small intestine adenocarcinoma, which can be detected. In theory patient 
with cancer harbouring the mutation adds  benefit from anti- ERBB2 therapy, but it 
does not yet have an established predictive value.16  On the other hand, alterations in 
the same biomarker in oesophagus/oesophagogastric junction adenocarcinoma are 
predictive of response to this targeted therapy.17
2. Status: Specific molecular alteration. 
Evaluation of the status of a biomarker implies specification of the molecular 
alterations that gives it clinical utility.  Determination of the specific alteration (i.e. 
activating mutation, translocation, overexpression, etc) conceptually corresponds to 
the exact molecular phenomenon involved. In this manner, the lack of KRAS/NRAS 
activating mutations in CRC predicts a favourable response to anti-EGFR therapy.14 
In contrast, the presence (not the lack) of activating KIT mutations in other malignant 
neoplasms, such as  melanoma or gastrointestinal stromal tumours (GISTs), predict 
response to imatinib therapy.18
3.  Level of detection.
The level at which the alteration is detected is also crucial in the evaluation of the 
biomarker status. The clinical utility of the biomarker can be detected at genetic, 
transcriptomic and/or at the protein level; specific mutations of KRAS, NRAS and 
BRAF in CRC are good examples of genetic level detection.19 Some alterations 
detected at the transcriptomic level are oncotype Dx in breast cancer20 and 
consensus molecular subtypes (CMS) in CRC.21 At the protein level, examples are c-
MET (mesenchymal-epithelial transition factor) in CRC or ALK (anaplastic lymphoma 
kinase) fusion in NSCLC, both could be detected by immunohistochemistry22-23. To 
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clinical significance, independent of the system/organ where it occurs. An example of 
this is ERBB2 in NSCLC in which  mutation is not associated with ERBB2 
amplification or overexpression, suggesting a distinct entity and a potential different 
therapeutic target.24 Conversely, evaluation of ERBB2 in gastric/gastroesophageal 
junction adenocarcinomas and breast carcinomas shows that gene amplification and 
protein overexpression are both useful  in prediction of  target therapies.25-26
Gastrointestinal system biomarkers update
1. General
A total of 54 different biomarkers are mentioned 98 times across the gastrointestinal 
tract chapters of the WHO blue book. Figure 2 summarises them, showing if the 
technology used corresponds to immunohistochemical (IHC) tests, transcriptomic 
tools or DNA-based mutational assays. Microsatellite instability (MSI) is described 
11 times, one for diagnostic, four for prognostic and six for therapeutic purposes.  
p53/TP53 is used ten times, three times as an IHC test, and seven as a DNA-
based mutational analysis tool. KRAS study is indicated on six occasions, all of 
which correspond to DNA mutational analysis with predictive utility, with one use 
as a potential prognostic biomarker. On the contrary, overexpression of ERBB2 is 
indicated five times, all using IHC, but considering that some cases will require 
confirmation by fluorescence in situ hybridisation (FISH). The organ with the most 
biomarkers mentioned was the small intestine/ampulla, with 31 different markers 
mentioned, the vast majority being prognostic specific markers with potential for 
future use.  Finally, the large intestine has more established biomarkers for current 
routine use than any other anatomic site, with 15 markers of diagnostic, 
established predictive and prognostic use.
The biomarkers discussed below are summarized by category, subcategory and 
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The routinely used molecular biomarkers in oesophageal lesions include the presence 
of aberrant immunohistochemical expression of p53, which may be  associated with a 
better diagnostic reproducibility of dysplasia (differential diagnosis biomarker) and an 
increased risk of neoplastic progression (prognostic risk stratification biomarker),  in 
the context of Barrett's oesophagus.27-28 In addition, ERBB2 overexpression and/or 
ERBB2 gene amplification in lower oesophagus/oesophagogastric junction 
adenocarcinoma carries a predictive value for response to ERBB2-targeted therapy 
(established predictive biomarker).17
There are other markers not yet used in routine pathological analysis, but they 
may be important in the near future.  EGFR protein overexpression in oesophageal 
squamous cell carcinoma is considered  an adverse prognostic specific factor10, 
because targeted therapies have not been successful in improving survival.11-12 The 
loss of MMR proteins expression (with the consequent MSI) and  overexpression of 
PD-L1 in oesophagus/oesophagogastric junction adenocarcinoma, are linked to the 
potential use of immune checkpoints inhibitors.  These checkpoint inhibitors are  
under clinical trial evaluation for immunotherapy 29, as  is CTLA4 overexpression 
(potentially predictive biomarkers).29-30
Other possible biomarkers are methylation of the CDKN2A (p16 promoter which 
inhibits its gene expression) and genomic instability (specifically copy number 
alterations). Both biomarkers have potential value as prognostic risk stratification 
biomarkers in Barrett dysplasia28, but this is not yet supported by strong retrospective 
or prospective studies.
3. Stomach
The molecular biomarkers with current use in gastric tumours include ERBB2 
overexpression and/or ERBB2 gene amplification in gastric adenocarcinoma and 
gastric undifferentiated carcinoma, with established predictive value for response to 
ERBB2-targeted therapy17,31,32 and the presence of MALAT1-GLI1 fusion gene for 
diagnostic confirmation of gastroblastoma, a rare gastric biphasic tumour recently 
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mutations also act as differential diagnosis biomarkers, helping to distinguishing 
gastric neuroendocrine carcinomas (NECs) from G3 neuroendocrine tumours (NETs), 
in which these genes are more frequently wildtype; this is also applicable for the 
remainder of the digestive organs.34
There is a plethora of markers used in gastric cancer biology, specifically with 
regard to prognostic specific markers, with little direct routine application. These 
include EGFR and c-MET overexpression31, MSI35, EBV(Epstein Barr virus) 
detection36, high expression levels of EGF(epidermal growth factor) /TGF-α 
(transforming growth factor alpha), VEGF-A (vascular endothelial growth factor-A) and 
CD44, reduced expression of E-cadherin, expression of matrix metalloproteinases 
(MMP1, MMP7 and MMP10), upregulation of SPC18 (SEC11A), and Protocadherin 
B9 (PCDHB9) overexpression.37-39 MSI and PD-L1 expression are potential predictive 
molecular biomarkers under investigation in clinical trials .35,40,41
Finally, for gastric dysplasia, there are biomarkers of disease progression that are 
seldom used routinely today. These are DNA content abnormalities (aneuploidy or 
elevated 4N fraction)42; aberrant p53/TP53; mutations of RNF43, APC (adenomatous 
polyposis coli), ARID (AT-rich interactive domain)1A and ARID2 43,44; and inactivation 
by promoter methylation of p16 and MLH1 (with consequent MSI) 45,46.
4. Small intestine and ampulla
In ampullary and non-ampullary adenocarcinomas, only MSI is a regularly used 
molecular biomarker. Its indication includes immunotherapy selection (established 
predictive biomarker), determination of a possible hereditary origin (differential 
diagnosis biomarker) and its use as a specific prognostic parameter (early results 
show that MSI may improve overall survival).47,48 Markers with potential specific 
prognostic value, but without regular pathological use, include KRAS activating 
mutations in ampullary adenocarcinoma19; Chromosome 18 deletion, chromosome 14 
gain, whole arm copy number variations, and CDKN1B mutations in small intestinal 
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Other biomarkers with potential prognostic specific or predictive pre-clinical value 
in non-ampullary adenocarcinoma are TP53, IDH (isocitrate dehydrogenase), CDH1 
(cadherin-1), FGFR2 (fibroblast growth factor receptor 2), FLT3 (fms-like tyrosine 
kinase 3), NPM1 (nucleophosmin) , PTEN (phosphatase and tensin homolog), c-MET, 
AKT1, RET (rearranged during transfection), NOTCH1 (neurogenic locus Notch 
homolog protein 1), ERBB4 (receptor tyrosine kinase 4/HER-4), CHN2 (beta-
chimaerin), KRAS, SMAD4 (mothers against decapentaplegic homolog 4), ERBB2 
and CTNNB1/E-Cadherin.16,52-55
5. Appendix
In appendiceal adenocarcinoma, multiple studies have been conducted , but there is 
insufficient evidence to make firm recommendations in  potentially predictive and pre-
clinical biomarkers (KRAS, MSI, GNAS [Guanine nucleotide-binding protein G]).56-58 
As in the rest of the digestive system, the presence of TP53 and RB1 mutations can 
help distinguish appendiceal neuroendocrine carcinomas (NECs) from G3 
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6. Colon and rectum
The molecular markers routinely used in CRC comprise the lack of activating 
mutations of KRAS/NRAS and BRAF (extended RAS testing), both with established 
predictive value for effective response to anti-EGFR therapy.14,59 BRAF activating 
mutations have differential diagnostic utility in the exclusion of Lynch syndrome and 
they are associated  with an adverse specific prognosis.60,61 MSI is an established 
predictive marker in colorectal adenocarcinoma associated with a significant response 
to PD-L1 inhibitors in patients who failed conventional therapy, confers a good 
prognosis to BRAF wildtype patients (specific prognostic marker) and is useful in 
Lynch syndrome diagnosis. 62
In addition, two different methods are being used for colorectal adenocarcinoma 
molecular diagnostic classification: genomic-scale analysis (hypermutated or non-
hypermutated colorectal cancers)63 and transcriptomic profiling (consensus molecular 
subtypes for colorectal cancer).21 Both have potential for sub-type based targeted 
therapies.
There are other markers in CRC that are not yet used currently, but show some 
promising results.  c-MET overexpression has potential predictive value for response 
to c-MET inhibitors.23 PIK3CA (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase 
Catalytic Subunit Alpha) activating mutations are associated with a worse specific 
prognosis, negative predicted response to anti-EGFR therapy, and a successful 
adjuvant response to acetylsalicylic acid.[64,65(p3)] Immune related markers like 
Immunoscore, represent a potential prognostic stratification tool 66,67 and gene 
expression signatures have a more restricted prognostic use, specifically for 
determining the risk of recurrence after surgery. 68,69
7. Anal canal
The molecular biomarkers with clinical utility are p16 expression and polymerase 
chain reaction (PCR) determination of high-risk human papilloma virus (HPV) 
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high-risk lesion to squamous cell carcinoma (SCC) is influenced by HPV genotype, 
immune status and other factors. 70-72 
Other markers with potential and/or pre-clinical predictive utility include PD-L1 
expression in SCC73,74; KRAS and NRAS lack of activating mutations and MSI in anal 
adenocarcinoma.75
Conclusion
Despite the significant knowledge on the molecular basis of cancers of the digestive tract, 
there are relatively few biomarkers with established clinical utility, and most target 
common tumour types. Our review follows the new WHO approach to molecular markers 
that is easily identifiable and also readily revisited when new information becomes 
available in the future. This systematic approach to the characterisation of new molecular 
markers may be used for the future taxonomy of cancers, which are also likely to benefit 
from computational pathology, especially within the next 5-year cycle of the WHO 
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Table 1. Pre-invasive molecular biomarkers by category, subcategory and evaluated 
organ of the gastrointestinal tract. 
Table 2. Invasive molecular biomarkers by category, subcategory and evaluated organ of 
the gastrointestinal tract.
Category Subcategory Oesophagus Stomach Small intestine/ampulla Appendix Colorectal Anal canal
Differential Diagnosis p53 (BD) ·· ·· ·· ·· ··Diagnostic
Cancer classification ·· ·· ·· ·· ·· ··
Established ·· ·· ·· ·· ·· ··
Potential ·· ·· ·· ·· ·· ··Predictive
Pre-clinical ·· ·· ·· ·· ·· ··
Specific ·· ·· ·· ·· ·· ··
p53 (BD) DNA CAb (GD) ·· ·· ·· p16 (ASD)
CDKN2A (BD) p53/TP53 (GD) ·· ·· ·· HPV (ASD)
Gen Inst (BD) RNF43 (GD) ·· ·· ·· ··
·· p16 (GD) ·· ·· ·· ··
·· APC (GD) ·· ·· ·· ··
·· ARID1A (GD) ·· ·· ·· ··
·· ARID2 (GD) ·· ·· ·· ··
Prognostic
Risk Stratification 
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Category Subcategory Oesophagus Stomach Small intestine/ampulla Appendix Colorectal Anal canal
·· MALAT1-GLI1 (GB) MSI (AAdC-NAAdC) TP53 (NEN) BRAF(AdC) TP53 (NEN)
·· TP53 (NEN) TP53 (NEN) RB1 (NEN) TP53 (NEN) RB1 (NEN)
·· RB1 (NEN) RB1 (NEN) ·· RB1 (NEN) ··
Differential Diagnosis
·· ·· ·· ·· MSI (CRC) ··
·· ·· ·· ·· CMS (AdC) ··
Diagnostic
Cancer classification
·· ·· ·· ·· GC (AdC)  
ERBB2 (AdC) ERBB2 (AdC-UC) MSI (AAdC-NAAdC) ·· KRAS (AdC) ··
·· ·· ·· ·· NRAS (AdC) ··
·· ·· ·· ·· BRAF(AdC) ··
·· ·· ·· ·· MSI (AdC) ··
Established
·· ·· ·· ·· PIK3CA (AdC) ··
MSI (AdC) MSI (AdC) ·· ·· c-MET (AdC) PD-L1 (SCC)
PDL1 (AdC) PDL1 (AdC) ·· ·· ·· ··Potential
CTLA4 (AdC)  ·· ·· ·· ··
EGFR (SCC) ·· BRAF (NAAdC) KRAS (ApAC) ·· KRAS (AdC)
·· ·· KRAS (NAAdC) MSI (ApAC) ·· NRAS (AdC)
·· ·· IDH1 (NAAdC) GNAS (ApAC) ·· MSI (AdC)
Predictive
Pre-clinical
·· ·· ERBB2 (NAAdC) ·· ·· ··
·· EGFR (AdC) MSI (AAdC-NAAdC) ·· BRAF(AdC) ··
·· c-MET(AdC) Chr 18 del (NEN) ·· MSI (AdC) ··
·· ERBB2 (AdC) Chr 14 gain (NEN) ·· PIK3CA (AdC) ··
·· MSI (AdC) WACNV (NEN) ·· ·· ··
·· EBV (AdC) CDKN1B (NEN) ·· ·· ··
·· EGF/TGF-α (AdC) KRAS (AAdC) ·· ·· ··
·· VEGF-A (AdC) TP53 (NAAdC) ·· ·· ··
·· CD44 (AdC) KRAS (NAAdC) ·· ·· ··
·· E-cadherin (AdC) CHN2 (NAAdC) ·· ·· ··
·· MMP1 (AdC) SMAD4 (NAAdC)  ·· ·· ··
·· MMP7 (AdC) KIT (NAAdC) ·· ·· ··
·· MMP10 (AdC) HER4 (NAAdC) ·· ·· ··
·· SPC18 (AdC) CDH1 (NAAdC) ·· ·· ··
·· PCDH B9 (AdC) FGFR2 (NAAdC) ·· ·· ··
·· ·· FLT3 (NAAdC) ·· ·· ··
·· ·· NPM1 (NAAdC) ·· ·· ··
·· ·· PTEN (NAAdC) ·· ·· ··
·· ·· c-MET (NAAdC) ·· ·· ··
·· ·· AKT1 (NAAdC) ·· ·· ··
·· ·· RET (NAAdC) ·· ·· ··
·· ·· NOTCH1 (NAAdC) ·· ·· ··
·· ·· CTNNB1/E Cadh (NAAdC) ·· ·· ··
Specific
·· ·· ERBB2 (NAAdC) ·· ·· ··
Prognostic
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Legends (tables and figures):
Figure 1. Proposed categorization of molecular biomarkers.
The subdivision in specific categories and subcategories improves the organization, 
facilitate their comprehension and allows an adequate update of molecular biomarkers.
Figure 2. Gastrointestinal molecular biomarkers frequency by detection technology.
Each square represents an individual count of a molecular biomarker in gastrointestinal 
system. The technologies of detection are: IHC test (Green); Transcriptomic tool (Blue); 
DNA-based mutational assays (Red). 
* In most cases MSI is studied by DNA-based mutational assays. However, in some 
organs like large intestine IHC is useful as a diagnostic biomarker of Lynch Syndrome 
while DNA-based mutational assays are used for predictive and prognostic analysis 
(Red/green square).
BD, Barret dysplasia; p53, Tumour suppressor protein p53; CDKN2A, Cyclin-dependent kinase Inhibitor 2A 
gene; Gen Inst, Genomic Instability; AdC, Adenocarcinoma; ERBB2, Human epidermal growth factor 
receptor 2; MSI, Microsatellite instability; PD-L1, Programmed Death-ligand 1; CTLA4, Cytotoxic T-
Lymphocyte Antigen 4; SCC, Squamous cell carcinoma; EGFR, Epidermal growth factor receptor; DNA 
CAb, deoxyribonucleic acid content abnormalities; GD, Gastric dysplasia; RNF43, Ring Finger Protein 43 
gene; APC, Adenomatous polyposis coli gene; ARID1A, AT-rich interactive domain-containing protein 1A 
gene; ARID2, AT-rich interactive domain-containing protein 2 gene; MLH1, MutL homolog 1 gene; p16, 
Protein p16; GB, Gastroblastoma; MALAT1-GLI1, MALAT1-GLI1 fusion gene; UC, Undifferentiated 
carcinoma; TP53, Tumour suppressor protein 53 gene; RB1, Retinoblastoma 1 gene; c-MET, tyrosine-
protein kinase Met receptor; EBV, Epstein-Barr virus, EGF/TGF-α, epidermal growth factor/ transforming 
growth factor alpha; VEGF-A, Vascular endothelial growth factor A; CD44, CD44 antigen; MMP1, Matrix 
metalloproteinase-1; MMP7, Matrix metalloproteinase-7; MMP10, Matrix metalloproteinase-10; SPC18, 
Septal Pore Cap Protein 18 gene; PCDH B9, Protocadherin B9; KRAS, Kirsten Rat Sarcoma Viral 
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Oncogene Homolog; IDH1, Isocitrate Dehydrogenase 1 gene; Chr 18 del, Chromosome 18 deletion; Chr 14 
gain, Chromosome 14 gain; WACNV, Whole arm copy number variation; CDK1B, Cyclin Dependent Kinase 
Inhibitor 1B gene; CHN2, Chimerin 2 gene; SMAD4, SMAD family member 4 gene; KIT, KIT proto-
oncogene, receptor tyrosine kinase; HER4, Human epidermal growth factor receptor 4 gene; CDH1, 
Cadherin 1 gene; FGFR2, fibroblast growth factor receptor 2 gene; FLT3, fms-like tyrosine kinase 3 gene; 
NPM1, Nucleophosmin 1 gene; PTEN, phosphatase and tensin homologue gene; MET, tyrosine-protein 
kinase Met gene; AKT1, AKT serine-threonine kinase 1 gene; RET, ret proto-oncogene; NOTCH1, Notch 
homolog 1 translocation-associated gene; CTNNB1, catenin beta 1 gene; NEN, Neuroendocrine 
neoplasms; AAdC, Ampullary adenocarcinoma; NAAdC, Non-ampullary adenocarcinoma; ApAC, 
appendiceal adenocarcinoma; GNAS, Guanine nucleotide-binding protein G gene; BRAF, Serine/threonine-
protein kinase B-raf gene; CMS, consensus molecular groups; GC, genomic classification; NRAS, NRAS 
proto-oncogene GTPase; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha 
gene; IS, Immunoscore; GES, gene expression signatures; ASD, Anal squamous dysplasia; HPV, human 
papilloma virus.
Table 1:
Abbreviations are the same used in figure 2.
Table 2:
Abbreviations are the same used in figure 2. 
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